AI in Biotechnology Market: Growth, Size, Share, and Trends

Report Code HIT 9205
Published in Oct, 2024, By MarketsandMarkets™
Download PDF

Choose License Type

Buy Report Now Inquire Before Buying

AI in Biotechnology Market by Function (Drug Design & Optimisation, Biomarker, SAR; Clinical Trial Design, Data Assessment, RWE, Inventory, Supply chain, Logistics; Launch, Pricing, Patient Engagement, Adverse Events), & End User - Global Forecast to 2029

Overview

The global AI in biotechnology market is projected to reach USD 7.75 billion by 2029 from USD 3.23 billion in 2024, at a high CAGR of 19.1% during the forecast period. The demand for advanced data analysis, precision medicine, and faster drug development is driving the growth of AI in biotechnology market. Machine learning enables more processing capabilities of vast biological datasets and improves accuracy within genomic analysis, protein engineering, and drug discovery. For instance, several significant factors driving the market dynamics include AI in predictive toxicology for late-stage drug safety, AI-assisted repurposing of existing drugs, and precision drug design using generative AI models. Besides, investments in biotechnology advancements along with a favorable regulatory environment drive the growth trajectory of the market. For instance, NVIDIA Corporation invested USD 50 million in Recursion Pharmaceuticals, Inc. as part of a private investment in public equity (PIPE). The companies collaborated to develop and distribute AI foundation models for drug discovery using NVIDIA's cloud services.

Attractive Opportunities in the AI in Biotechnology Market

North America

The North American region offers potential growth opportunities for most biotechnology companies, owing to its high per-capita healthcare expenditure, Strategic AI partnerships with tech giants, and ongoing technological advancements.

Factors such as AI-enhanced Real-World Evidence (RWE) integration, regulatory advancements supporting AI integration, and venture capital surge in AI-driven biotech startups are expected to drive the growth of this market

AI and quantum computing synergy for next-generation drug discovery and adoption of AI in biologics and gene therapy development are expected to offer lucrative opportunities for market players in the next five years.

The AI in biotechnology market is expected to be worth USD 3.22 billion by 2029, growing at CAGR of 18.5% during the forecast period.

The high market growth in North America can be attributed to the substantial funding for AI-based startups and research projects for the development and deployment of AI solutions within the biotechnology sector.

Global AI in Biotechnology Market Dynamics

DRIVER: Growing need to reduce the time and cost of drug discovery and development.

Drug discovery in biotechnology is a very costly and lengthy process, owing to which there is a need for alternative tools for discovering new drugs. Even though in vitro and in vivo methods are expensive and lengthy, they are generally applied in drug discovery & development. Developing a new medicine usually takes 10–15 years and costs up to USD 2.8 billion on average. (Source: ScienceDirect). Although the number of new molecular entities (NMEs) approved by regulatory agencies, such as the US Food and Drug Administration (FDA), has increased over the past decade (2010-2019) compared with the prior decade, the cost of bringing a new drug to market has risen precipitously. The key causes of increasing costs for pharmaceutical innovation include losses from investments in later-stage clinical failures, a stringent regulatory environment that demands higher standards for approval, and inflated clinical trial costs where the most expensive trials are generally those of pivotal studies. Under these conditions, drug and biotechnology companies are driven to innovate and integrate new technologies to increase productivity, decrease costs, and ensure profitability.

Most drug candidates selected in the discovery phase fail in the late stages of development due to toxicity or other pharmacokinetic characteristics. Machine learning technology can help at this stage by predicting the outcome of a drug compound in the discovery phase and eliminating compounds without potential in the early discovery phase itself. This will drastically reduce time and costs associated with finding possible medication candidates.

RESTRAINT: High implementation costs of AI limit adoption in biotechnology, especially for SMEs and emerging economies

Despite Al's revolutionary promise in biotechnology, a significant barrier is the expensive expense of implementing and maintaining complex Al systems. The costs associated with these solutions, including subscription and licensing fees, can range from USD 10,000 to several million dollars, depending on various factors such as application areas, solution types, and data volume. For many biotechnology companies, especially small- and medium-sized enterprises (SMEs) and contract research organizations (CROs), these high costs are prohibitive. The financial impact is particularly noticeable in emerging economies since budgets often set greater importance on investing on medical equipment than on IT. Due to this, advanced AI technologies are not typically employed in these areas, which restricts the potential of big data for useful evaluation by smaller businesses.

 

OPPORTUNITY: Integrating AI and big data in precision medicine for biotechnology advancement

Precision medicine creates personalized medical therapies based on individual genomic data. Predictive modeling and advanced analytics in biotechnology open up novel opportunities for targeted treatment, thereby improving patient outcomes. AI-assisted analytics are gaining a firm footing by targeting areas of health such as diabetes and cancer treatment. AI definitively could be the key factor in changing precision health as entirely new, data-driven methods will be introduced to patient care companies that are looking for funding to run such specific medicine solutions.

The large funds that are injected indicate a breakthrough in the Al biotechnology sector and this could very well be the beginning of the era of precision medicine. Machine learning and advanced analytics provide the market with unrivaled insights in patient care. Al is also seen as the ground for advanced medical processes aside from enhancing the therapeutic effects.

CHALLENGES: Data quality and interpretability issues that hinder AI integration and trustworthiness

The major concern to overcome by the biotechnology companies is the availability and quality of data. Biotech research is a source of a lot of data but it is conveyed haphazardly and lack standardization, so the formulas of Al can't extract significant insights. Machine learning and data analytics technologies are the only methods that can push the biotechnology market to its development. Nevertheless, without first-rate well-working datasets, this may become a real obstacle to the appearance of efficient machine-learning tools in drug discovery, precision medicine, and other fields of application.

Furthermore, data quality and interpretability are essential issues to be considered when AI techniques are used. Many of deep learning or other types of AI can produce high-precision predictions, although they are often viewed as black boxes since the process they go through for their decision-making remains obscure. This opaqueness is what gives rise to vulnerability linked to reliability in such areas as the pharmaceutical industry. A survey conducted by the Biocom Institute along with over 70% of biotechnology professionals revealed that the ethical issues and reliability of Al computer digital minds were the most widely recognized. The cure will be to develop and adapt technologies and systems such as Al more responsibly, which will be a crucial challenge in the biotechnology sector. Most importantly, where the immaterial improvement of data and the proper assessment of policies will play a greater role. Besides, the want of trust and the being of counterfeits respectively.

Global AI in Biotechnology Market Ecosystem Analysis

The ecosystem of the AI in biotechnology market involves various stakeholders, technologies, and trends that contribute to the development and application of AI solutions. Key stakeholders, including network, connectivity and hardware providers; infrastructure service providers; AI software and service providers; CROs, pharmaceutical & biotechnology companies; government and regulatory bodies, research centers, academic, & government institutes; start ups.

Source: Annual Reports, Press Releases, Investor Presentations, Expert Interviews, and MarketsandMarkets Analysis

 

Cloud-based solutions lead AI biotechnology market by ensuring data security and supporting advanced technologies.

On the basis of the deployment model, the AI in biotechnology market is segmented into cloud-based and on-premise. In 2023, the cloud-based segment accounted for the largest share of the AI in biotechnology market. The growth in this segment is attributed to cloud services providing strong backup options and recovery plans, which help protect important data and keep businesses running smoothly, which is critical for the sensitive nature of biotechnological data. Moreover, cloud-based AI tools can integrate with newer emerging technologies such as the Internet of Things (IoT) and edge computing. Such integration enhances data analysis and supports more complex applications in biotechnology. Also, the computing power of biotech companies will easily respond to alteration by changing data requirements. This is because biotech companies with cloud can easily analyze large amounts of data used in research processes, such as genomics and drug development.

By function, research & development accounted for the largest segment of AI in biotechnology market

The AI in biotechnology market by function is broadly divided into six segments: research & development, regulatory compliance, manufacturing & supply chain, launch & commercial, and post-market surveillance & patient support. Research & development held the largest market share in 2023. It is divided into two major segments such as drug discovery and clinical development. Developing an effective drug is a lengthy and expensive process. R&D efforts can be driven toward increased efficiency and effectiveness by utilizing AI's potential to speed up research procedures, improve decision-making, promote cross-disciplinary cooperation, facilitate predictive modeling, and optimize resource allocation. However, all AI tools in research and development, need to be evaluated ethically, taking into account issues like security, privacy, data protection, and unexpected consequences. Transparency is essential to ensuring that stakeholders and researchers are informed about decision-making procedures.

North America accounted for the largest market share in 2023.

In 2023, North America held the largest share of the AI in biotechnology market. The region has favourable regulatory frameworks from agencies such as the FDA that encourage the adoption of AI in biopharma, allowing for accelerated approvals for AI-assisted diagnostics and therapies. and the North America holds many biotech start-ups mostly in the US. Huge innovation and collaboration are prevailing in the areas that lead to tremendous advancement in AI application.

HIGHEST CAGR MARKET IN 2023
US FASTEST GROWING MARKET IN THE REGION

Recent Developments of AI in Biotechnology Market

  • In August 2024, Exscientia plc (UK) announced a definitive agreement with Recursion Pharmaceuticals, Inc. (US) to combine their capabilities, creating a global technology-enabled drug discovery leader. The combination aims to leverage Recursion’s scaled biology exploration with Exscientia’s precision chemistry design.
  • In June 2024, SOPHiA GENETICS (Switzerland) partnered with Strand Life Sciences (India) to combine expertise in genomics, bioinformatics, and diagnostics to enhance data analysis and develop innovative solutions for improved patient care.
  • In January 2024, NVIDIA Corporation collaborated with Amgen to develop AI models for drug discovery using NVIDIA DGX SuperPOD, harnessing one of the world's largest human datasets.
  • In March 2023, Predictive Oncology (US) collaborated with Integra Therapeutics (Spain) to enhance gene editing capabilities for cancer therapies using Predictive Oncology’s protein expression expertise.

Key Market Players

Want to explore hidden markets that can drive new revenue in AI in Biotechnology Market?

Scope of the Report

Report Metric Details
Market size available for years 2022-2029
Base Year Considered 2023
Forecast period 2024-2029
Forecast units Million/Billion (USD)
Segments covered Offering, Function, Deployment Mode, and End User
Geographies covered North America, Europe, Asia Pacific, Latin America and Middle East and Africa

 

Key Questions Addressed by the Report

Which are the top industry players in the global AI in biotechnology market?
The top market players in the global AI in biotechnology market include NVIDIA Corporation (US), Illumina, Inc. (US), Exscientia plc (UK), Schrödinger, Inc. (US), Recursion Pharmaceuticals, Inc. (US), SOPHiA GENETICS (Switzerland), Predictive Oncology. (US), Deep Genomics. (Canada), Data4Cure, Inc. (US), Genoox (US), BenevolentAI (US), DNAnexus, Inc. (US), Tempus (US), NuMedii, Inc. (US), XtalPi Inc. (US), Lifebit Biotech Ltd (England), BPGbio, Inc. (US), Valo Health (US), VeriSIM Life. (US), Iktos. (France), Insilico Medicine (US), Eurofins Discovery. (US), Logica. (US), American Chemical Society (US), Aganitha AI Inc. (India).
Which end users have been included in the AI in biotechnology market report?
This report contains the following end users in AI in biotechnology market:
  • Pharmaceutical companies
  • Biotechnology companies
  • Research institutes and labs
  • Healthcare providers
  • Contract research organizations (CRO)
Which geographical region is dominating in the global AI in biotechnology market?
The global AI in biotechnology market is segmented into North America, Europe, Asia Pacific, Latin America, the Middle East & Africa. North America holds the largest share during the forecast period.
Which deployment model segments have been included in the AI in biotechnology market report?
The report contains the following deployment model segments:
  • Cloud-based
    • Public Cloud
    • Private Cloud
    • Multi-cloud
    • Hybrid Cloud
  • On-premise
What is the total CAGR expected to be recorded for the AI in biotechnology market during 2024-2029?
The CAGR is expected to record a CAGR of 19.1% from 2024-2029

 

Personalize This Research

  • Triangulate with your Own Data
  • Get Data as per your Format and Definition
  • Gain a Deeper Dive on a Specific Application, Geography, Customer or Competitor
  • Any level of Personalization
Request A Free Customisation

Let Us Help You

  • What are the Known and Unknown Adjacencies Impacting the AI in Biotechnology Market
  • What will your New Revenue Sources be?
  • Who will be your Top Customer; what will make them switch?
  • Defend your Market Share or Win Competitors
  • Get a Scorecard for Target Partners
Customized Workshop Request

Table of Contents

Exclusive indicates content/data unique to MarketsandMarkets and not available with any competitors.

TITLE
PAGE NO
INTRODUCTION
37
RESEARCH METHODOLOGY
43
EXECUTIVE SUMMARY
56
PREMIUM INSIGHTS
60
MARKET OVERVIEW
64
  • 5.1 INTRODUCTION
  • 5.2 MARKET DYNAMICS
    DRIVERS
    - Growing cross-industry collaborations and partnerships
    - Growing need to reduce time and cost of drug discovery and development
    - Rising adoption of AI in precision medicine
    - Improving computing power and declining hardware cost
    RESTRAINTS
    - High implementation costs of AI limit adoption in biotechnology, especially for SMEs and emerging economies
    - Data privacy risks and compliance challenges for AI in biotechnology
    OPPORTUNITIES
    - Integrating AI and big data in precision medicine for biotechnology advancement
    - Surge in biotechnology investments enhances opportunities for AI to accelerate drug discovery innovations
    - Innovation across healthcare, agriculture, and environmental science for global growth
    CHALLENGES
    - Data quality and interpretability issues that hinder AI integration and trustworthiness
    - AI deployment in biotechnology hindered by talent shortages and evolving regulatory challenges
  • 5.3 ECOSYSTEM ANALYSIS
  • 5.4 CASE STUDY ANALYSIS
    LEVERAGED NVIDIA DGX CLOUD FOR RAPID TRAINING OF PROTEIN MODELS
    IMPLEMENTED END-TO-END NGS WORKFLOW FOR EFFICIENT GENETIC VARIANT DETECTION
    ACCELERATED DRUG DISCOVERY WITH GENERATIVE AI AND STREAMLINED WORKFLOWS
  • 5.5 VALUE CHAIN ANALYSIS
  • 5.6 PORTER'S FIVE FORCES ANALYSIS
    BARGAINING POWER OF SUPPLIERS
    BARGAINING POWER OF BUYERS
    THREAT OF SUBSTITUTES
    THREAT OF NEW ENTRANTS
    INTENSITY OF COMPETITIVE RIVALRY
  • 5.7 REGULATORY ANALYSIS
    REGULATORY LANDSCAPE
    - North America
    - Europe
    - Asia Pacific
    - Latin America
    - Middle East & Africa
    REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
  • 5.8 PATENT ANALYSIS
    PATENT PUBLICATION TRENDS FOR AI IN BIOTECHNOLOGY
    JURISDICTION AND TOP APPLICANT ANALYSIS
  • 5.9 TECHNOLOGY ANALYSIS
    KEY TECHNOLOGIES
    - Natural Language Processing (NLP)
    - Predictive analytics
    COMPLEMENTARY TECHNOLOGIES
    - Cloud computing
    - Big data analytics
  • 5.10 INDUSTRY TRENDS
    EVOLUTION OF AI IN BIOTECHNOLOGY
    COMPUTER-AIDED DRUG DESIGN AND AI
  • 5.11 PRICING ANALYSIS
    INDICATIVE PRICING ANALYSIS, BY DRUG DISCOVERY PROCESS
    AVERAGE SELLING PRICE TREND, BY REGION
  • 5.12 KEY CONFERENCES & EVENTS, 2024–2025
  • 5.13 KEY STAKEHOLDERS & BUYING CRITERIA
    BUYING CRITERIA
  • 5.14 TRENDS & DISRUPTIONS IMPACTING CUSTOMERS’ BUSINESSES
  • 5.15 END-USER ANALYSIS
    UNMET NEEDS
    END-USER EXPECTATIONS
  • 5.16 INVESTMENT & FUNDING SCENARIO
  • 5.17 IMPACT OF AI/GEN AI ON AI IN BIOTECHNOLOGY MARKET
    KEY USE CASES
    CASE STUDIES OF AI/GENERATIVE AI IMPLEMENTATION
    - Case study: Accelerated biomarker discovery and clinical trial optimization
    IMPACT OF AI/GEN AI ON INTERCONNECTED AND ADJACENT ECOSYSTEMS
    - Drug discovery and development market
    - Genomics and bioinformatics market
    - Medical imaging & diagnostics market
    USER READINESS & IMPACT ASSESSMENT
    - User readiness
    - Impact assessment
AI IN BIOTECHNOLOGY MARKET, BY OFFERING
102
  • 6.1 INTRODUCTION
  • 6.2 END-TO-END SOLUTIONS
    GROWING USE OF ADVANCED ALGORITHMS TO IMPROVE PRECISION AND EFFICIENCY TO BOOST MARKET GROWTH
  • 6.3 NICHE SOLUTIONS
    ABILITY OF NICHE SOLUTIONS TO ADDRESS SPECIFIC CHALLENGES WITHIN DRUG DISCOVERY TO SUPPORT ADOPTION
  • 6.4 TECHNOLOGIES
    ABILITY OF TECHNOLOGIES TO ENHANCE DRUG DISCOVERY, PERSONALIZED MEDICINE, AND DATA ANALYTICS TO FUEL GROWTH
  • 6.5 SERVICES
    CONSULTING SERVICES
    - Increasing efficiency of research processes and cost savings to boost adoption of consulting services
    IMPLEMENTATION SERVICES & ONGOING IT SUPPORT
    - Increasing precision and efficiency in IT support services to boost demand
    TRAINING & EDUCATION SERVICES
    - Need for skilled talent to drive market growth
    POST-SALES & MAINTENANCE SERVICES
    - Complexity of AI systems and need for improvement in AI algorithms to boost market
AI IN BIOTECHNOLOGY MARKET, BY FUNCTION
111
  • 7.1 INTRODUCTION
  • 7.2 RESEARCH & DEVELOPMENT
    DRUG DISCOVERY
    - Molecular design & optimization
    - Biomarker discovery
    - Structure-activity relationship (SAR) modeling
    CLINICAL DEVELOPMENT
    - Trial design
    - Site selection
    - Recruitment
    - Clinical data assessment
    - Predictive toxicity & risk monitoring
    - Monitoring & drug adherence
    - Real-world evidence (RWE) analysis
  • 7.3 REGULATORY COMPLIANCE
    ABILITY OF AI TO ENSURE REGULATORY COMPLIANCE IN CLINICAL TRIALS TO SUPPORT GROWTH
  • 7.4 MANUFACTURING & SUPPLY CHAIN
    SUPPLY CHAIN PLANNING
    - Increasing demand for real-time data analytics to accelerate market growth
    INVENTORY MANAGEMENT
    - Automating stock tracking and replenishment with advanced analytics to fuel growth
    LOGISTICS OPTIMIZATION
    - Ability of AI to drive collaboration and transparency in biotechnology logistics to aid growth
    DEMAND FORECASTING
    - Ability to integrate data for reliable demand forecasts to fuel growth
    PREDICTIVE MAINTENANCE
    - Boosting equipment reliability with AI-powered predictive maintenance to drive demand
    OTHER MANUFACTURING & SUPPLY CHAIN FUNCTIONS
  • 7.5 LAUNCH & COMMERCIAL
    LAUNCH COORDINATION
    - Growing product launch success rates through predictive analytics to boost adoption
    PATIENT ENGAGEMENT
    - Advantages such as real-time patient feedback for better health outcomes to support growth
    MARKETING OPERATIONS
    - Enhanced marketing performance with AI to boost market
    PREDICTIVE PRICING
    - Ability of AI to enhance pricing accuracy to drive adoption
  • 7.6 POST-MARKETING SURVEILLANCE & PATIENT SUPPORT
    MEDICATION ADHERENCE
    - Growing demand for personalized healthcare to drive market
    ADVERSE EVENT REPORTING
    - Advantages such as faster post-market surveillance and enhanced drug safety to drive demand
    PATIENT MONITORING
    - Rise of remote healthcare solutions to boost demand
    COMPLIANCE MONITORING
    - Increasing complexity of regulatory requirements to drive adoption
    PATIENT SUPPORT PROGRAMS
    - Growing interest in patient-centered care to support growth
  • 7.7 CORPORATE
    RISK MANAGEMENT
    - Rising expenditure for drug development to support growth
    COMPLIANCE MONITORING
    - Strict guidelines from bodies to aid growth
    SALES FORCE OPTIMIZATION
    - Need for data-driven decision-making to boost adoption of sales force optimization
    OTHER CORPORATE FUNCTIONS
AI IN BIOTECHNOLOGY MARKET, BY DEPLOYMENT MODE
142
  • 8.1 INTRODUCTION
  • 8.2 CLOUD-BASED SOLUTIONS
    PUBLIC CLOUD
    - Need to reduce dependency on expensive on-premise infrastructure to boost demand
    PRIVATE CLOUD
    - Need for enhanced security and data protection to drive market growth
    MULTI-CLOUD
    - Enhanced flexibility & cost optimization to support market growth
    HYBRID CLOUD
    - Cost efficiency and flexibility of hybrid cloud to fuel growth
  • 8.3 ON-PREMISE SOLUTIONS
    ADVANTAGES SUCH AS DATA SECURITY AND PRIVACY AND COMPLIANCE WITH REGULATIONS TO FAVOR GROWTH
AI IN BIOTECHNOLOGY MARKET, BY END USER
150
  • 9.1 INTRODUCTION
  • 9.2 PHARMACEUTICAL COMPANIES
    INNOVATION AND EFFICIENCY ASSOCIATED WITH AI INTEGRATION IN DRUG DISCOVERY & DEVELOPMENT TO BOOST ADOPTION
  • 9.3 BIOTECHNOLOGY COMPANIES
    ABILITY OF AI-DRIVEN INNOVATIONS TO ACCELERATE PERSONALIZED MEDICINE AND DRUG DISCOVERY TO SUPPORT GROWTH
  • 9.4 RESEARCH INSTITUTES & LABS
    STRATEGIC INVESTMENTS AND COLLABORATIONS TO PROPEL AI ADVANCEMENTS IN RESEARCH INSTITUTES AND LABS
  • 9.5 HEALTHCARE PROVIDERS
    IMPROVED PATIENT OUTCOMES TO SUPPORT ADOPTION
  • 9.6 CONTRACT RESEARCH ORGANIZATIONS (CROS)
    ABILITY OF AI TECHNOLOGIES TO ACCELERATE CLINICAL TRIALS AND IMPROVE PATIENT RECRUITMENT TO FUEL GROWTH
AI IN BIOTECHNOLOGY MARKET, BY REGION
157
  • 10.1 INTRODUCTION
  • 10.2 NORTH AMERICA
    MACROECONOMIC OUTLOOK FOR NORTH AMERICA
    US
    - Increasing investments and partnerships to drive market
    CANADA
    - Availability of advanced facilities and shorter approval times for drug candidates to drive market
  • 10.3 EUROPE
    MACROECONOMIC OUTLOOK FOR EUROPE
    GERMANY
    - Increased funding in start-ups to drive uptake of AI in biotechnology
    UK
    - Increasing investments and government fund allocations to drive market
    FRANCE
    - Government initiatives in France to support market growth
    ITALY
    - Growing investments to create opportunities for market growth
    SPAIN
    - Increasing need for personalized medicine and data-driven healthcare to increase adoption rate in market
    REST OF EUROPE
  • 10.4 ASIA PACIFIC
    MACROECONOMIC OUTLOOK FOR ASIA PACIFIC
    JAPAN
    - Accelerating AI-driven drug discovery and biotechnology innovation to drive market in Japan
    CHINA
    - Rising foreign investments to drive market in China
    INDIA
    - Increasing number of start-ups and support from government to propel market
    SOUTH KOREA
    - Significant advances in AI integration for R&D to fuel growth
    REST OF ASIA PACIFIC
  • 10.5 LATIN AMERICA
    MACROECONOMIC OUTLOOK FOR LATIN AMERICA
    BRAZIL
    - Funding of biotech companies to drive market in Brazil
    MEXICO
    - Investment inflows and strengthening AI-related education to drive market in Mexico
    REST OF LATIN AMERICA
  • 10.6 MIDDLE EAST & AFRICA
    MACROECONOMIC OUTLOOK FOR MIDDLE EAST & AFRICA
    GCC COUNTRIES
    - Increase in healthcare investments to support market growth
    REST OF MIDDLE EAST & AFRICA
COMPETITIVE LANDSCAPE
300
  • 11.1 INTRODUCTION
  • 11.2 KEY PLAYER STRATEGY/RIGHT TO WIN
  • 11.3 REVENUE ANALYSIS, 2019–2023
  • 11.4 MARKET SHARE ANALYSIS, 2023
    RANKING OF KEY MARKET PLAYERS
  • 11.5 COMPANY EVALUATION MATRIX: KEY PLAYERS, 2023
    STARS
    EMERGING LEADERS
    PERVASIVE PLAYERS
    PARTICIPANTS
    COMPANY FOOTPRINT: KEY PLAYERS, 2023
    - Company footprint
    - Component footprint
    - Application footprint
    - End-user footprint
    - Region footprint
  • 11.6 COMPANY EVALUATION MATRIX: START-UPS/SMES, 2023
    PROGRESSIVE COMPANIES
    RESPONSIVE COMPANIES
    DYNAMIC COMPANIES
    STARTING BLOCKS
    COMPETITIVE BENCHMARKING: STARTUPS/SMES, 2023
  • 11.7 COMPANY VALUATION & FINANCIAL METRICS
  • 11.8 BRAND/PRODUCT COMPARISON
  • 11.9 COMPETITIVE SCENARIO
    PRODUCT LAUNCHES & UPGRADES
    DEALS
    EXPANSIONS
COMPANY PROFILES
322
  • 12.1 KEY PLAYERS
    NVIDIA CORPORATION
    - Business overview
    - Products offered
    - Recent developments
    - MnM view
    ILLUMINA, INC.
    - Business overview
    - Products offered
    - Recent developments
    - MnM view
    EXSCIENTIA
    - Business overview
    - Products offered
    - Recent developments
    - MnM view
    SCHRÖDINGER, INC.
    - Business overview
    - Products offered
    - Recent developments
    RECURSION PHARMACEUTICALS, INC.
    - Business overview
    - Products offered
    - Recent developments
    SOPHIA GENETICS
    - Business overview
    - Products offered
    - Recent developments
    PREDICTIVE ONCOLOGY
    - Business overview
    - Products offered
    - Recent developments
    BENEVOLENTAI
    - Business overview
    - Products offered
    - Recent developments
    EUROFINS DISCOVERY
    - Business overview
    - Products offered
    - Recent developments
    XTALPI INC.
    - Business overview
    - Products offered
    - Recent developments
    DNANEXUS, INC.
    - Business overview
    - Products offered
    - Recent developments
    NUMEDII, INC.
    - Business overview
    - Products offered
    BPGBIO, INC.
    - Business overview
    - Products offered
    - Recent developments
    IKTOS.
    - Business overview
    - Products offered
    - Recent developments
    INSILICO MEDICINE
    - Business overview
    - Products offered
    LOGICA
    - Business overview
    - Products offered
    AMERICAN CHEMICAL SOCIETY
    - Business overview
    - Products offered
    AGANITHA AI INC.
    - Business overview
    - Products offered
    - Recent developments
  • 12.2 START-UP/SME PLAYERS
    VERISIM LIFE
    VALO HEALTH
    TEMPUS AI, INC.
    LIFEBIT BIOTECH LTD.
    GENOOX
    DATA4CURE, INC.
    DEEP GENOMICS
APPENDIX
375
  • 13.1 DISCUSSION GUIDE
  • 13.2 KNOWLEDGESTORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL
  • 13.3 CUSTOMIZATION OPTIONS
  • 13.4 RELATED REPORTS
  • 13.5 AUTHOR DETAILS
LIST OF TABLES
 
  • TABLE 1 EXCHANGE RATES UTILIZED FOR CONVERSION TO USD
  • TABLE 2 INDICATIVE LIST OF COLLABORATIONS AND PARTNERSHIPS IN AI IN BIOTECHNOLOGY MARKET (2021−2024)
  • TABLE 3 AI IN BIOTECHNOLOGY MARKET: PORTER’S FIVE FORCES ANALYSIS
  • TABLE 4 NORTH AMERICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
  • TABLE 5 EUROPE: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
  • TABLE 6 ASIA PACIFIC: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
  • TABLE 7 REST OF THE WORLD: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
  • TABLE 8 LIST OF PATENTS/PATENT APPLICATIONS IN AI IN BIOTECHNOLOGY MARKET, 2021–2024
  • TABLE 9 AI IN BIOTECHNOLOGY MARKET: INDICATIVE PRICING, BY DRUG DISCOVERY PROCESS
  • TABLE 10 AI IN BIOTECHNOLOGY MARKET: KEY CONFERENCES & EVENTS, 2024–2025
  • TABLE 11 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS OF TOP 3 END USERS (%)
  • TABLE 12 KEY BUYING CRITERIA FOR TOP 3 END USERS
  • TABLE 13 UNMET NEEDS IN AI IN BIOTECHNOLOGY MARKET
  • TABLE 14 END-USER EXPECTATIONS IN AI IN BIOTECHNOLOGY MARKET
  • TABLE 15 AI IN BIOTECHNOLOGY MARKET, BY OFFERING, 2022–2029 (USD MILLION)
  • TABLE 16 AI IN BIOTECHNOLOGY MARKET FOR END-TO-END SOLUTIONS, BY REGION, 2022–2029 (USD MILLION)
  • TABLE 17 AI IN BIOTECHNOLOGY MARKET FOR NICHE SOLUTIONS, BY REGION, 2022–2029 (USD MILLION)
  • TABLE 18 AI IN BIOTECHNOLOGY MARKET FOR TECHNOLOGIES, BY REGION, 2022–2029 (USD MILLION)
  • TABLE 19 AI IN BIOTECHNOLOGY MARKET FOR SERVICES, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 20 AI IN BIOTECHNOLOGY MARKET FOR SERVICES, BY REGION, 2022–2029 (USD MILLION)
  • TABLE 21 AI IN BIOTECHNOLOGY MARKET FOR CONSULTING SERVICES, BY REGION, 2022–2029 (USD MILLION)
  • TABLE 22 AI IN BIOTECHNOLOGY MARKET FOR IMPLEMENTATION SERVICES & ONGOING IT SUPPORT, BY REGION, 2022–2029 (USD MILLION)
  • TABLE 23 AI IN BIOTECHNOLOGY MARKET FOR TRAINING & EDUCATION SERVICES, BY REGION, 2022–2029 (USD MILLION)
  • TABLE 24 AI IN BIOTECHNOLOGY MARKET FOR POST-SALES & MAINTENANCE SERVICES, BY REGION, 2022–2029 (USD MILLION)
  • TABLE 25 AI IN BIOTECHNOLOGY MARKET, BY FUNCTION, 2022–2029 (USD MILLION)
  • TABLE 26 AI IN BIOTECHNOLOGY MARKET FOR RESEARCH & DEVELOPMENT FUNCTIONS, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 27 AI IN BIOTECHNOLOGY MARKET FOR RESEARCH & DEVELOPMENT FUNCTIONS, BY REGION, 2022–2029 (USD MILLION)
  • TABLE 28 EXAMPLES OF AI TOOLS USED IN DRUG DISCOVERY
  • TABLE 29 AI IN BIOTECHNOLOGY MARKET FOR DRUG DISCOVERY, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 30 AI IN BIOTECHNOLOGY MARKET FOR DRUG DISCOVERY, BY REGION, 2022–2029 (USD MILLION)
  • TABLE 31 AI IN BIOTECHNOLOGY MARKET FOR MOLECULAR DESIGN & OPTIMIZATION, BY REGION, 2022–2029 (USD MILLION)
  • TABLE 32 AI IN BIOTECHNOLOGY MARKET FOR BIOMARKER DISCOVERY, BY REGION, 2022–2029 (USD MILLION)
  • TABLE 33 AI IN BIOTECHNOLOGY MARKET FOR STRUCTURE-ACTIVITY RELATIONSHIP (SAR) MODELING, BY REGION, 2022–2029 (USD MILLION)
  • TABLE 34 AI IN BIOTECHNOLOGY MARKET FOR CLINICAL DEVELOPMENT, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 35 AI IN BIOTECHNOLOGY MARKET FOR CLINICAL DEVELOPMENT, BY REGION, 2022–2029 (USD MILLION)
  • TABLE 36 AI IN BIOTECHNOLOGY MARKET FOR TRIAL DESIGN, BY REGION, 2022–2029 (USD MILLION)
  • TABLE 37 AI IN BIOTECHNOLOGY MARKET FOR SITE SELECTION, BY REGION, 2022–2029 (USD MILLION)
  • TABLE 38 AI IN BIOTECHNOLOGY MARKET FOR RECRUITMENT, BY REGION, 2022–2029 (USD MILLION)
  • TABLE 39 AI IN BIOTECHNOLOGY MARKET FOR CLINICAL DATA ASSESSMENT, BY REGION, 2022–2029 (USD MILLION)
  • TABLE 40 AI IN BIOTECHNOLOGY MARKET FOR PREDICTIVE TOXICITY & RISK MONITORING, BY REGION, 2022–2029 (USD MILLION)
  • TABLE 41 AI IN BIOTECHNOLOGY MARKET FOR MONITORING & DRUG ADHERENCE, BY REGION, 2022–2029 (USD MILLION)
  • TABLE 42 AI IN BIOTECHNOLOGY MARKET FOR REAL-WORLD EVIDENCE (RWE) ANALYSIS, BY REGION, 2022–2029 (USD MILLION)
  • TABLE 43 AI IN BIOTECHNOLOGY MARKET FOR REGULATORY COMPLIANCE FUNCTIONS, BY REGION, 2022–2029 (USD MILLION)
  • TABLE 44 AI IN BIOTECHNOLOGY MARKET FOR MANUFACTURING & SUPPLY CHAIN FUNCTIONS, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 45 AI IN BIOTECHNOLOGY MARKET FOR MANUFACTURING & SUPPLY CHAIN FUNCTIONS, BY REGION, 2022–2029 (USD MILLION)
  • TABLE 46 AI IN BIOTECHNOLOGY MARKET FOR SUPPLY CHAIN PLANNING, BY REGION, 2022–2029 (USD MILLION)
  • TABLE 47 AI IN BIOTECHNOLOGY MARKET FOR INVENTORY MANAGEMENT, BY REGION, 2022–2029 (USD MILLION)
  • TABLE 48 AI IN BIOTECHNOLOGY MARKET FOR LOGISTICS OPTIMIZATION, BY REGION, 2022–2029 (USD MILLION)
  • TABLE 49 AI IN BIOTECHNOLOGY MARKET FOR DEMAND FORECASTING, BY REGION, 2022–2029 (USD MILLION)
  • TABLE 50 AI IN BIOTECHNOLOGY MARKET FOR PREDICTIVE MAINTENANCE, BY REGION, 2022–2029 (USD MILLION)
  • TABLE 51 AI IN BIOTECHNOLOGY MARKET FOR OTHER MANUFACTURING & SUPPLY CHAIN FUNCTIONS, BY REGION, 2022–2029 (USD MILLION)
  • TABLE 52 AI IN BIOTECHNOLOGY MARKET FOR LAUNCH & COMMERCIAL FUNCTIONS, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 53 AI IN BIOTECHNOLOGY MARKET FOR LAUNCH & COMMERCIAL FUNCTIONS, BY REGION, 2022–2029 (USD MILLION)
  • TABLE 54 AI IN BIOTECHNOLOGY MARKET FOR LAUNCH COORDINATION, BY REGION, 2022–2029 (USD MILLION)
  • TABLE 55 AI IN BIOTECHNOLOGY MARKET FOR PATIENT ENGAGEMENT, BY REGION, 2022–2029 (USD MILLION)
  • TABLE 56 AI IN BIOTECHNOLOGY MARKET FOR MARKETING OPERATIONS, BY REGION, 2022–2029 (USD MILLION)
  • TABLE 57 AI IN BIOTECHNOLOGY MARKET FOR PREDICTIVE PRICING, BY REGION, 2022–2029 (USD MILLION)
  • TABLE 58 AI IN BIOTECHNOLOGY MARKET FOR POST-MARKETING SURVEILLANCE & PATIENT SUPPORT FUNCTIONS, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 59 AI IN BIOTECHNOLOGY MARKET FOR POST-MARKETING SURVEILLANCE & PATIENT SUPPORT FUNCTIONS, BY REGION, 2022–2029 (USD MILLION)
  • TABLE 60 AI IN BIOTECHNOLOGY MARKET FOR MEDICATION ADHERENCE, BY REGION, 2022–2029 (USD MILLION)
  • TABLE 61 AI IN BIOTECHNOLOGY MARKET FOR ADVERSE EVENT REPORTING, BY REGION, 2022–2029 (USD MILLION)
  • TABLE 62 AI IN BIOTECHNOLOGY MARKET FOR PATIENT MONITORING, BY REGION, 2022–2029 (USD MILLION)
  • TABLE 63 AI IN BIOTECHNOLOGY MARKET FOR COMPLIANCE MONITORING, BY REGION, 2022–2029 (USD MILLION)
  • TABLE 64 AI IN BIOTECHNOLOGY MARKET FOR PATIENT SUPPORT PROGRAMS, BY REGION, 2022–2029 (USD MILLION)
  • TABLE 65 AI IN BIOTECHNOLOGY MARKET FOR CORPORATE FUNCTIONS, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 66 AI IN BIOTECHNOLOGY MARKET FOR CORPORATE FUNCTIONS, BY REGION, 2022–2029 (USD MILLION)
  • TABLE 67 AI IN BIOTECHNOLOGY MARKET FOR RISK MANAGEMENT, BY REGION, 2022–2029 (USD MILLION)
  • TABLE 68 AI IN BIOTECHNOLOGY MARKET FOR COMPLIANCE MONITORING, BY REGION, 2022–2029 (USD MILLION)
  • TABLE 69 AI IN BIOTECHNOLOGY MARKET FOR SALES FORCE OPTIMIZATION, BY REGION, 2022–2029 (USD MILLION)
  • TABLE 70 AI IN BIOTECHNOLOGY MARKET FOR OTHER CORPORATE FUNCTIONS, BY REGION, 2022–2029 (USD MILLION)
  • TABLE 71 AI IN BIOTECHNOLOGY MARKET, BY DEPLOYMENT MODE, 2022–2029 (USD MILLION)
  • TABLE 72 AI IN BIOTECHNOLOGY MARKET FOR CLOUD-BASED SOLUTIONS, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 73 AI IN BIOTECHNOLOGY MARKET FOR CLOUD-BASED SOLUTIONS, BY REGION, 2022–2029 (USD MILLION)
  • TABLE 74 AI IN BIOTECHNOLOGY MARKET FOR PUBLIC CLOUD, BY REGION, 2022–2029 (USD MILLION)
  • TABLE 75 AI IN BIOTECHNOLOGY MARKET FOR PRIVATE CLOUD, BY REGION, 2022–2029 (USD MILLION)
  • TABLE 76 AI IN BIOTECHNOLOGY MARKET FOR MULTI-CLOUD, BY REGION, 2022–2029 (USD MILLION)
  • TABLE 77 AI IN BIOTECHNOLOGY MARKET FOR HYBRID CLOUD, BY REGION, 2022–2029 (USD MILLION)
  • TABLE 78 AI IN BIOTECHNOLOGY MARKET FOR ON-PREMISE SOLUTIONS, BY REGION, 2022–2029 (USD MILLION)
  • TABLE 79 AI IN BIOTECHNOLOGY MARKET, BY END USER, 2022–2029 (USD MILLION)
  • TABLE 80 AI IN BIOTECHNOLOGY MARKET FOR PHARMACEUTICAL COMPANIES, BY REGION, 2022–2029 (USD MILLION)
  • TABLE 81 AI IN BIOTECHNOLOGY MARKET FOR BIOTECHNOLOGY COMPANIES, BY REGION, 2022–2029 (USD MILLION)
  • TABLE 82 AI IN BIOTECHNOLOGY MARKET FOR RESEARCH INSTITUTES & LABS, BY REGION, 2022–2029 (USD MILLION)
  • TABLE 83 AI IN BIOTECHNOLOGY MARKET FOR HEALTHCARE PROVIDERS, BY REGION, 2022–2029 (USD MILLION)
  • TABLE 84 AI IN BIOTECHNOLOGY MARKET FOR CONTRACT RESEARCH ORGANIZATIONS (CROS), BY REGION, 2022–2029 (USD MILLION)
  • TABLE 85 AI IN BIOTECHNOLOGY MARKET, BY REGION, 2022–2029 (USD MILLION)
  • TABLE 86 NORTH AMERICA: AI IN BIOTECHNOLOGY MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 87 NORTH AMERICA: AI IN BIOTECHNOLOGY MARKET, BY OFFERING, 2022–2029 (USD MILLION)
  • TABLE 88 NORTH AMERICA: AI IN BIOTECHNOLOGY MARKET FOR SERVICES, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 89 NORTH AMERICA: AI IN BIOTECHNOLOGY MARKET, BY FUNCTION, 2022–2029 (USD MILLION)
  • TABLE 90 NORTH AMERICA: AI IN BIOTECHNOLOGY MARKET FOR RESEARCH & DEVELOPMENT FUNCTIONS, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 91 NORTH AMERICA: AI IN BIOTECHNOLOGY MARKET FOR DRUG DISCOVERY, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 92 NORTH AMERICA: AI IN BIOTECHNOLOGY MARKET FOR CLINICAL DEVELOPMENT, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 93 NORTH AMERICA: AI IN BIOTECHNOLOGY MARKET FOR MANUFACTURING & SUPPLY CHAIN FUNCTIONS, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 94 NORTH AMERICA: AI IN BIOTECHNOLOGY MARKET FOR LAUNCH & COMMERCIAL FUNCTIONS, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 95 NORTH AMERICA: AI IN BIOTECHNOLOGY MARKET FOR POST-MARKETING SURVEILLANCE & PATIENT SUPPORT FUNCTIONS, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 96 NORTH AMERICA: AI IN BIOTECHNOLOGY MARKET FOR CORPORATE FUNCTIONS, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 97 NORTH AMERICA: AI IN BIOTECHNOLOGY MARKET, BY DEPLOYMENT MODE, 2022–2029 (USD MILLION)
  • TABLE 98 NORTH AMERICA: AI IN BIOTECHNOLOGY MARKET FOR CLOUD-BASED SOLUTIONS, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 99 NORTH AMERICA: AI IN BIOTECHNOLOGY MARKET, BY END USER, 2022–2029 (USD MILLION)
  • TABLE 100 US: AI IN BIOTECHNOLOGY MARKET, BY OFFERING, 2022–2029 (USD MILLION)
  • TABLE 101 US: AI IN BIOTECHNOLOGY MARKET FOR SERVICES, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 102 US: AI IN BIOTECHNOLOGY MARKET, BY FUNCTION, 2022–2029 (USD MILLION)
  • TABLE 103 US: AI IN BIOTECHNOLOGY MARKET FOR RESEARCH & DEVELOPMENT FUNCTIONS, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 104 US: AI IN BIOTECHNOLOGY MARKET FOR DRUG DISCOVERY, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 105 US: AI IN BIOTECHNOLOGY MARKET FOR CLINICAL DEVELOPMENT, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 106 US: AI IN BIOTECHNOLOGY MARKET FOR MANUFACTURING & SUPPLY CHAIN FUNCTIONS, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 107 US: AI IN BIOTECHNOLOGY MARKET FOR LAUNCH & COMMERCIAL FUNCTIONS, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 108 US: AI IN BIOTECHNOLOGY MARKET FOR POST-MARKETING SURVEILLANCE & PATIENT SUPPORT FUNCTIONS, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 109 US: AI IN BIOTECHNOLOGY MARKET FOR CORPORATE FUNCTIONS, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 110 US: AI IN BIOTECHNOLOGY MARKET, BY DEPLOYMENT MODE, 2022–2029 (USD MILLION)
  • TABLE 111 US: AI IN BIOTECHNOLOGY MARKET FOR CLOUD-BASED SOLUTIONS, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 112 US: AI IN BIOTECHNOLOGY MARKET, BY END USER, 2022–2029 (USD MILLION)
  • TABLE 113 CANADA: AI IN BIOTECHNOLOGY MARKET, BY OFFERING, 2022–2029 (USD MILLION)
  • TABLE 114 CANADA: AI IN BIOTECHNOLOGY MARKET FOR SERVICES, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 115 CANADA: AI IN BIOTECHNOLOGY MARKET, BY FUNCTION, 2022–2029 (USD MILLION)
  • TABLE 116 CANADA: AI IN BIOTECHNOLOGY MARKET FOR RESEARCH & DEVELOPMENT FUNCTIONS, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 117 CANADA: AI IN BIOTECHNOLOGY MARKET FOR DRUG DISCOVERY, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 118 CANADA: AI IN BIOTECHNOLOGY MARKET FOR CLINICAL DEVELOPMENT, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 119 CANADA: AI IN BIOTECHNOLOGY MARKET FOR MANUFACTURING & SUPPLY CHAIN FUNCTIONS, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 120 CANADA: AI IN BIOTECHNOLOGY MARKET FOR LAUNCH & COMMERCIAL FUNCTIONS, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 121 CANADA: AI IN BIOTECHNOLOGY MARKET FOR POST-MARKETING SURVEILLANCE & PATIENT SUPPORT FUNCTIONS, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 122 CANADA: AI IN BIOTECHNOLOGY MARKET FOR CORPORATE FUNCTIONS, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 123 CANADA: AI IN BIOTECHNOLOGY MARKET, BY DEPLOYMENT MODE, 2022–2029 (USD MILLION)
  • TABLE 124 CANADA: AI IN BIOTECHNOLOGY MARKET FOR CLOUD-BASED SOLUTIONS, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 125 CANADA: AI IN BIOTECHNOLOGY MARKET, BY END USER, 2022–2029 (USD MILLION)
  • TABLE 126 EUROPE: AI IN BIOTECHNOLOGY MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 127 EUROPE: AI IN BIOTECHNOLOGY MARKET, BY OFFERING, 2022–2029 (USD MILLION)
  • TABLE 128 EUROPE: AI IN BIOTECHNOLOGY MARKET FOR SERVICES, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 129 EUROPE: AI IN BIOTECHNOLOGY MARKET, BY FUNCTION, 2022–2029 (USD MILLION)
  • TABLE 130 EUROPE: AI IN BIOTECHNOLOGY MARKET FOR RESEARCH & DEVELOPMENT FUNCTIONS, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 131 EUROPE: AI IN BIOTECHNOLOGY MARKET FOR DRUG DISCOVERY, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 132 EUROPE: AI IN BIOTECHNOLOGY MARKET FOR CLINICAL DEVELOPMENT, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 133 EUROPE: AI IN BIOTECHNOLOGY MARKET FOR MANUFACTURING & SUPPLY CHAIN FUNCTIONS, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 134 EUROPE: AI IN BIOTECHNOLOGY MARKET FOR LAUNCH & COMMERCIAL FUNCTIONS, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 135 EUROPE: AI IN BIOTECHNOLOGY MARKET FOR POST-MARKETING SURVEILLANCE & PATIENT SUPPORT FUNCTIONS, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 136 EUROPE: AI IN BIOTECHNOLOGY MARKET FOR CORPORATE FUNCTIONS, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 137 EUROPE: AI IN BIOTECHNOLOGY MARKET, BY DEPLOYMENT MODE, 2022–2029 (USD MILLION)
  • TABLE 138 EUROPE: AI IN BIOTECHNOLOGY MARKET FOR CLOUD-BASED SOLUTIONS, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 139 EUROPE: AI IN BIOTECHNOLOGY MARKET, BY END USER, 2022–2029 (USD MILLION)
  • TABLE 140 GERMANY: AI IN BIOTECHNOLOGY MARKET, BY OFFERING, 2022–2029 (USD MILLION)
  • TABLE 141 GERMANY: AI IN BIOTECHNOLOGY MARKET FOR SERVICES, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 142 GERMANY: AI IN BIOTECHNOLOGY MARKET, BY FUNCTION, 2022–2029 (USD MILLION)
  • TABLE 143 GERMANY: AI IN BIOTECHNOLOGY MARKET FOR RESEARCH & DEVELOPMENT FUNCTIONS, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 144 GERMANY: AI IN BIOTECHNOLOGY MARKET FOR DRUG DISCOVERY, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 145 GERMANY: AI IN BIOTECHNOLOGY MARKET FOR CLINICAL DEVELOPMENT, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 146 GERMANY: AI IN BIOTECHNOLOGY MARKET FOR MANUFACTURING & SUPPLY CHAIN FUNCTIONS, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 147 GERMANY: AI IN BIOTECHNOLOGY MARKET FOR LAUNCH & COMMERCIAL FUNCTIONS, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 148 GERMANY: AI IN BIOTECHNOLOGY MARKET FOR POST-MARKETING SURVEILLANCE & PATIENT SUPPORT FUNCTIONS, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 149 GERMANY: AI IN BIOTECHNOLOGY MARKET FOR CORPORATE FUNCTIONS, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 150 GERMANY: AI IN BIOTECHNOLOGY MARKET, BY DEPLOYMENT MODE, 2022–2029 (USD MILLION)
  • TABLE 151 GERMANY: AI IN BIOTECHNOLOGY MARKET FOR CLOUD-BASED SOLUTIONS, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 152 GERMANY: AI IN BIOTECHNOLOGY MARKET, BY END USER, 2022–2029 (USD MILLION)
  • TABLE 153 UK: AI IN BIOTECHNOLOGY MARKET, BY OFFERING, 2022–2029 (USD MILLION)
  • TABLE 154 UK: AI IN BIOTECHNOLOGY MARKET FOR SERVICES, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 155 UK: AI IN BIOTECHNOLOGY MARKET, BY FUNCTION, 2022–2029 (USD MILLION)
  • TABLE 156 UK: AI IN BIOTECHNOLOGY MARKET FOR RESEARCH & DEVELOPMENT FUNCTIONS, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 157 UK: AI IN BIOTECHNOLOGY MARKET FOR DRUG DISCOVERY, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 158 UK: AI IN BIOTECHNOLOGY MARKET FOR CLINICAL DEVELOPMENT, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 159 UK: AI IN BIOTECHNOLOGY MARKET FOR MANUFACTURING & SUPPLY CHAIN FUNCTIONS, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 160 UK: AI IN BIOTECHNOLOGY MARKET FOR LAUNCH & COMMERCIAL FUNCTIONS, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 161 UK: AI IN BIOTECHNOLOGY MARKET FOR POST-MARKETING SURVEILLANCE & PATIENT SUPPORT FUNCTIONS, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 162 UK: AI IN BIOTECHNOLOGY MARKET FOR CORPORATE FUNCTIONS, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 163 UK: AI IN BIOTECHNOLOGY MARKET, BY DEPLOYMENT MODE, 2022–2029 (USD MILLION)
  • TABLE 164 UK: AI IN BIOTECHNOLOGY MARKET FOR CLOUD-BASED SOLUTIONS, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 165 UK: AI IN BIOTECHNOLOGY MARKET, BY END USER, 2022–2029 (USD MILLION)
  • TABLE 166 FRANCE: AI IN BIOTECHNOLOGY MARKET, BY OFFERING, 2022–2029 (USD MILLION)
  • TABLE 167 FRANCE: AI IN BIOTECHNOLOGY MARKET FOR SERVICES, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 168 FRANCE: AI IN BIOTECHNOLOGY MARKET, BY FUNCTION, 2022–2029 (USD MILLION)
  • TABLE 169 FRANCE: AI IN BIOTECHNOLOGY MARKET FOR RESEARCH & DEVELOPMENT FUNCTIONS, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 170 FRANCE: AI IN BIOTECHNOLOGY MARKET FOR DRUG DISCOVERY, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 171 FRANCE: AI IN BIOTECHNOLOGY MARKET FOR CLINICAL DEVELOPMENT, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 172 FRANCE: AI IN BIOTECHNOLOGY MARKET FOR MANUFACTURING & SUPPLY CHAIN FUNCTIONS, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 173 FRANCE: AI IN BIOTECHNOLOGY MARKET FOR LAUNCH & COMMERCIAL FUNCTIONS, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 174 FRANCE: AI IN BIOTECHNOLOGY MARKET FOR POST-MARKETING SURVEILLANCE & PATIENT SUPPORT FUNCTIONS, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 175 FRANCE: AI IN BIOTECHNOLOGY MARKET FOR CORPORATE FUNCTIONS, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 176 FRANCE: AI IN BIOTECHNOLOGY MARKET, BY DEPLOYMENT MODE, 2022–2029 (USD MILLION)
  • TABLE 177 FRANCE: AI IN BIOTECHNOLOGY MARKET FOR CLOUD-BASED SOLUTIONS, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 178 FRANCE: AI IN BIOTECHNOLOGY MARKET, BY END USER, 2022–2029 (USD MILLION)
  • TABLE 179 ITALY: AI IN BIOTECHNOLOGY MARKET, BY OFFERING, 2022–2029 (USD MILLION)
  • TABLE 180 ITALY: AI IN BIOTECHNOLOGY MARKET FOR SERVICES, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 181 ITALY: AI IN BIOTECHNOLOGY MARKET, BY FUNCTION, 2022–2029 (USD MILLION)
  • TABLE 182 ITALY: AI IN BIOTECHNOLOGY MARKET FOR RESEARCH & DEVELOPMENT FUNCTIONS, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 183 ITALY: AI IN BIOTECHNOLOGY MARKET FOR DRUG DISCOVERY, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 184 ITALY: AI IN BIOTECHNOLOGY MARKET FOR CLINICAL DEVELOPMENT, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 185 ITALY: AI IN BIOTECHNOLOGY MARKET FOR MANUFACTURING & SUPPLY CHAIN FUNCTIONS, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 186 ITALY: AI IN BIOTECHNOLOGY MARKET FOR LAUNCH & COMMERCIAL FUNCTIONS, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 187 ITALY: AI IN BIOTECHNOLOGY MARKET FOR POST-MARKETING SURVEILLANCE & PATIENT SUPPORT FUNCTIONS, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 188 ITALY: AI IN BIOTECHNOLOGY MARKET FOR CORPORATE FUNCTIONS, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 189 ITALY: AI IN BIOTECHNOLOGY MARKET, BY DEPLOYMENT MODE, 2022–2029 (USD MILLION)
  • TABLE 190 ITALY: AI IN BIOTECHNOLOGY MARKET FOR CLOUD-BASED SOLUTIONS, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 191 ITALY: AI IN BIOTECHNOLOGY MARKET, BY END USER, 2022–2029 (USD MILLION)
  • TABLE 192 SPAIN: AI IN BIOTECHNOLOGY MARKET, BY OFFERING, 2022–2029 (USD MILLION)
  • TABLE 193 SPAIN: AI IN BIOTECHNOLOGY MARKET FOR SERVICES, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 194 SPAIN: AI IN BIOTECHNOLOGY MARKET, BY FUNCTION, 2022–2029 (USD MILLION)
  • TABLE 195 SPAIN: AI IN BIOTECHNOLOGY MARKET FOR RESEARCH & DEVELOPMENT FUNCTIONS, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 196 SPAIN: AI IN BIOTECHNOLOGY MARKET FOR DRUG DISCOVERY, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 197 SPAIN: AI IN BIOTECHNOLOGY MARKET FOR CLINICAL DEVELOPMENT, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 198 SPAIN: AI IN BIOTECHNOLOGY MARKET FOR MANUFACTURING & SUPPLY CHAIN FUNCTIONS, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 199 SPAIN: AI IN BIOTECHNOLOGY MARKET FOR LAUNCH & COMMERCIAL FUNCTIONS, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 200 SPAIN: AI IN BIOTECHNOLOGY MARKET FOR POST-MARKETING SURVEILLANCE & PATIENT SUPPORT FUNCTIONS, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 201 SPAIN: AI IN BIOTECHNOLOGY MARKET FOR CORPORATE FUNCTIONS, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 202 SPAIN: AI IN BIOTECHNOLOGY MARKET, BY DEPLOYMENT MODE, 2022–2029 (USD MILLION)
  • TABLE 203 SPAIN: AI IN BIOTECHNOLOGY MARKET FOR CLOUD-BASED SOLUTIONS, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 204 SPAIN: AI IN BIOTECHNOLOGY MARKET, BY END USER, 2022–2029 (USD MILLION)
  • TABLE 205 REST OF EUROPE: AI IN BIOTECHNOLOGY MARKET, BY OFFERING, 2022–2029 (USD MILLION)
  • TABLE 206 REST OF EUROPE: AI IN BIOTECHNOLOGY MARKET FOR SERVICES, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 207 REST OF EUROPE: AI IN BIOTECHNOLOGY MARKET, BY FUNCTION, 2022–2029 (USD MILLION)
  • TABLE 208 REST OF EUROPE: AI IN BIOTECHNOLOGY MARKET FOR RESEARCH & DEVELOPMENT FUNCTIONS, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 209 REST OF EUROPE: AI IN BIOTECHNOLOGY MARKET FOR DRUG DISCOVERY, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 210 REST OF EUROPE: AI IN BIOTECHNOLOGY MARKET FOR CLINICAL DEVELOPMENT, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 211 REST OF EUROPE: AI IN BIOTECHNOLOGY MARKET FOR MANUFACTURING & SUPPLY CHAIN FUNCTIONS, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 212 REST OF EUROPE: AI IN BIOTECHNOLOGY MARKET FOR LAUNCH & COMMERCIAL FUNCTIONS, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 213 REST OF EUROPE: AI IN BIOTECHNOLOGY MARKET FOR POST-MARKETING SURVEILLANCE & PATIENT SUPPORT FUNCTIONS, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 214 REST OF EUROPE: AI IN BIOTECHNOLOGY MARKET FOR CORPORATE FUNCTIONS, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 215 REST OF EUROPE: AI IN BIOTECHNOLOGY MARKET, BY DEPLOYMENT MODE, 2022–2029 (USD MILLION)
  • TABLE 216 REST OF EUROPE: AI IN BIOTECHNOLOGY MARKET FOR CLOUD-BASED SOLUTIONS, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 217 REST OF EUROPE: AI IN BIOTECHNOLOGY MARKET, BY END USER, 2022–2029 (USD MILLION)
  • TABLE 218 ASIA PACIFIC: AI IN BIOTECHNOLOGY MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 219 ASIA PACIFIC: AI IN BIOTECHNOLOGY MARKET, BY OFFERING, 2022–2029 (USD MILLION)
  • TABLE 220 ASIA PACIFIC: AI IN BIOTECHNOLOGY MARKET FOR SERVICES, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 221 ASIA PACIFIC: AI IN BIOTECHNOLOGY MARKET, BY FUNCTION, 2022–2029 (USD MILLION)
  • TABLE 222 ASIA PACIFIC: AI IN BIOTECHNOLOGY MARKET FOR RESEARCH & DEVELOPMENT FUNCTIONS, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 223 ASIA PACIFIC: AI IN BIOTECHNOLOGY MARKET FOR DRUG DISCOVERY, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 224 ASIA PACIFIC: AI IN BIOTECHNOLOGY MARKET FOR CLINICAL DEVELOPMENT, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 225 ASIA PACIFIC: AI IN BIOTECHNOLOGY MARKET FOR MANUFACTURING & SUPPLY CHAIN FUNCTIONS, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 226 ASIA PACIFIC: AI IN BIOTECHNOLOGY MARKET FOR LAUNCH & COMMERCIAL FUNCTIONS, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 227 ASIA PACIFIC: AI IN BIOTECHNOLOGY MARKET FOR POST-MARKETING SURVEILLANCE & PATIENT SUPPORT FUNCTIONS, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 228 ASIA PACIFIC: AI IN BIOTECHNOLOGY MARKET FOR CORPORATE FUNCTIONS, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 229 ASIA PACIFIC: AI IN BIOTECHNOLOGY MARKET, BY DEPLOYMENT MODE, 2022–2029 (USD MILLION)
  • TABLE 230 ASIA PACIFIC: AI IN BIOTECHNOLOGY MARKET FOR CLOUD-BASED SOLUTIONS, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 231 ASIA PACIFIC: AI IN BIOTECHNOLOGY MARKET, BY END USER, 2022–2029 (USD MILLION)
  • TABLE 232 JAPAN: AI IN BIOTECHNOLOGY MARKET, BY OFFERING, 2022–2029 (USD MILLION)
  • TABLE 233 JAPAN: AI IN BIOTECHNOLOGY MARKET FOR SERVICES, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 234 JAPAN: AI IN BIOTECHNOLOGY MARKET, BY FUNCTION, 2022–2029 (USD MILLION)
  • TABLE 235 JAPAN: AI IN BIOTECHNOLOGY MARKET FOR RESEARCH & DEVELOPMENT FUNCTIONS, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 236 JAPAN: AI IN BIOTECHNOLOGY MARKET FOR DRUG DISCOVERY, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 237 JAPAN: AI IN BIOTECHNOLOGY MARKET FOR CLINICAL DEVELOPMENT, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 238 JAPAN: AI IN BIOTECHNOLOGY MARKET FOR MANUFACTURING & SUPPLY CHAIN FUNCTIONS, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 239 JAPAN: AI IN BIOTECHNOLOGY MARKET FOR LAUNCH & COMMERCIAL FUNCTIONS, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 240 JAPAN: AI IN BIOTECHNOLOGY MARKET, BY POST-MARKETING SURVEILLANCE & PATIENT SUPPORT FUNCTIONS, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 241 JAPAN: AI IN BIOTECHNOLOGY MARKET FOR CORPORATE FUNCTIONS, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 242 JAPAN: AI IN BIOTECHNOLOGY MARKET, BY DEPLOYMENT MODE, 2022–2029 (USD MILLION)
  • TABLE 243 JAPAN: AI IN BIOTECHNOLOGY MARKET FOR CLOUD-BASED SOLUTIONS, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 244 JAPAN: AI IN BIOTECHNOLOGY MARKET, BY END USER, 2022–2029 (USD MILLION)
  • TABLE 245 CHINA: AI IN BIOTECHNOLOGY MARKET, BY OFFERING, 2022–2029 (USD MILLION)
  • TABLE 246 CHINA: AI IN BIOTECHNOLOGY MARKET FOR SERVICES, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 247 CHINA: AI IN BIOTECHNOLOGY MARKET, BY FUNCTION, 2022–2029 (USD MILLION)
  • TABLE 248 CHINA: AI IN BIOTECHNOLOGY MARKET FOR RESEARCH & DEVELOPMENT FUNCTIONS, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 249 CHINA: AI IN BIOTECHNOLOGY MARKET FOR DRUG DISCOVERY, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 250 CHINA: AI IN BIOTECHNOLOGY MARKET FOR CLINICAL DEVELOPMENT, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 251 CHINA: AI IN BIOTECHNOLOGY MARKET FOR MANUFACTURING & SUPPLY CHAIN FUNCTIONS, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 252 CHINA: AI IN BIOTECHNOLOGY MARKET FOR LAUNCH & COMMERCIAL FUNCTIONS, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 253 CHINA: AI IN BIOTECHNOLOGY MARKET, BY POST-MARKETING SURVEILLANCE & PATIENT SUPPORT FUNCTIONS, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 254 CHINA: AI IN BIOTECHNOLOGY MARKET FOR CORPORATE FUNCTIONS, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 255 CHINA: AI IN BIOTECHNOLOGY MARKET, BY DEPLOYMENT MODE, 2022–2029 (USD MILLION)
  • TABLE 256 CHINA: AI IN BIOTECHNOLOGY MARKET FOR CLOUD-BASED SOLUTIONS, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 257 CHINA: AI IN BIOTECHNOLOGY MARKET, BY END USER, 2022–2029 (USD MILLION)
  • TABLE 258 INDIA: AI IN BIOTECHNOLOGY MARKET, BY OFFERING, 2022–2029 (USD MILLION)
  • TABLE 259 INDIA: AI IN BIOTECHNOLOGY MARKET FOR SERVICES, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 260 INDIA: AI IN BIOTECHNOLOGY MARKET, BY FUNCTION, 2022–2029 (USD MILLION)
  • TABLE 261 INDIA: AI IN BIOTECHNOLOGY MARKET FOR RESEARCH & DEVELOPMENT FUNCTIONS, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 262 INDIA: AI IN BIOTECHNOLOGY MARKET FOR DRUG DISCOVERY, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 263 INDIA: AI IN BIOTECHNOLOGY MARKET FOR CLINICAL DEVELOPMENT, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 264 INDIA: AI IN BIOTECHNOLOGY MARKET FOR MANUFACTURING & SUPPLY CHAIN FUNCTIONS, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 265 INDIA: AI IN BIOTECHNOLOGY MARKET FOR LAUNCH & COMMERCIAL FUNCTIONS, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 266 INDIA: AI IN BIOTECHNOLOGY MARKET FOR POST-MARKETING SURVEILLANCE & PATIENT SUPPORT FUNCTIONS, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 267 INDIA: AI IN BIOTECHNOLOGY MARKET FOR CORPORATE FUNCTIONS, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 268 INDIA: AI IN BIOTECHNOLOGY MARKET, BY DEPLOYMENT MODE, 2022–2029 (USD MILLION)
  • TABLE 269 INDIA: AI IN BIOTECHNOLOGY MARKET FOR CLOUD-BASED SOLUTIONS, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 270 INDIA: AI IN BIOTECHNOLOGY MARKET, BY END USER, 2022–2029 (USD MILLION)
  • TABLE 271 SOUTH KOREA: AI IN BIOTECHNOLOGY MARKET, BY OFFERING, 2022–2029 (USD MILLION)
  • TABLE 272 SOUTH KOREA: AI IN BIOTECHNOLOGY MARKET FOR SERVICES, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 273 SOUTH KOREA: AI IN BIOTECHNOLOGY MARKET, BY FUNCTION, 2022–2029 (USD MILLION)
  • TABLE 274 SOUTH KOREA: AI IN BIOTECHNOLOGY MARKET FOR RESEARCH & DEVELOPMENT FUNCTIONS, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 275 SOUTH KOREA: AI IN BIOTECHNOLOGY MARKET FOR DRUG DISCOVERY, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 276 SOUTH KOREA: AI IN BIOTECHNOLOGY MARKET FOR CLINICAL DEVELOPMENT, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 277 SOUTH KOREA: AI IN BIOTECHNOLOGY MARKET FOR MANUFACTURING & SUPPLY CHAIN FUNCTIONS, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 278 SOUTH KOREA: AI IN BIOTECHNOLOGY MARKET FOR LAUNCH & COMMERCIAL FUNCTIONS, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 279 SOUTH KOREA: AI IN BIOTECHNOLOGY MARKET FOR POST-MARKETING SURVEILLANCE & PATIENT SUPPORT FUNCTIONS, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 280 SOUTH KOREA: AI IN BIOTECHNOLOGY MARKET FOR CORPORATE FUNCTIONS, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 281 SOUTH KOREA: AI IN BIOTECHNOLOGY MARKET, BY DEPLOYMENT MODE, 2022–2029 (USD MILLION)
  • TABLE 282 SOUTH KOREA: AI IN BIOTECHNOLOGY MARKET FOR CLOUD-BASED SOLUTIONS, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 283 SOUTH KOREA: AI IN BIOTECHNOLOGY MARKET, BY END USER, 2022–2029 (USD MILLION)
  • TABLE 284 REST OF ASIA PACIFIC: AI IN BIOTECHNOLOGY MARKET, BY OFFERING, 2022–2029 (USD MILLION)
  • TABLE 285 REST OF ASIA PACIFIC: AI IN BIOTECHNOLOGY MARKET FOR SERVICES, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 286 REST OF ASIA PACIFIC: AI IN BIOTECHNOLOGY MARKET, BY FUNCTION, 2022–2029 (USD MILLION)
  • TABLE 287 REST OF ASIA PACIFIC: AI IN BIOTECHNOLOGY MARKET FOR RESEARCH & DEVELOPMENT FUNCTIONS, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 288 REST OF ASIA PACIFIC: AI IN BIOTECHNOLOGY MARKET FOR DRUG DISCOVERY, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 289 REST OF ASIA PACIFIC: AI IN BIOTECHNOLOGY MARKET FOR CLINICAL DEVELOPMENT, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 290 REST OF ASIA PACIFIC: AI IN BIOTECHNOLOGY MARKET FOR MANUFACTURING & SUPPLY CHAIN FUNCTIONS, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 291 REST OF ASIA PACIFIC: AI IN BIOTECHNOLOGY MARKET FOR LAUNCH & COMMERCIAL FUNCTIONS, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 292 REST OF ASIA PACIFIC: AI IN BIOTECHNOLOGY MARKET FOR POST-MARKETING SURVEILLANCE & PATIENT SUPPORT FUNCTIONS, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 293 REST OF ASIA PACIFIC: AI IN BIOTECHNOLOGY MARKET FOR CORPORATE FUNCTIONS, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 294 REST OF ASIA PACIFIC: AI IN BIOTECHNOLOGY MARKET, BY DEPLOYMENT MODE, 2022–2029 (USD MILLION)
  • TABLE 295 REST OF ASIA PACIFIC: AI IN BIOTECHNOLOGY MARKET FOR CLOUD-BASED SOLUTIONS, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 296 REST OF ASIA PACIFIC: AI IN BIOTECHNOLOGY MARKET, BY END USER, 2022–2029 (USD MILLION)
  • TABLE 297 LATIN AMERICA: AI IN BIOTECHNOLOGY MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 298 LATIN AMERICA: AI IN BIOTECHNOLOGY MARKET, BY OFFERING, 2022–2029 (USD MILLION)
  • TABLE 299 LATIN AMERICA: AI IN BIOTECHNOLOGY MARKET FOR SERVICES, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 300 LATIN AMERICA: AI IN BIOTECHNOLOGY MARKET, BY FUNCTION, 2022–2029 (USD MILLION)
  • TABLE 301 LATIN AMERICA: AI IN BIOTECHNOLOGY MARKET FOR RESEARCH & DEVELOPMENT FUNCTIONS, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 302 LATIN AMERICA: AI IN BIOTECHNOLOGY MARKET FOR DRUG DISCOVERY, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 303 LATIN AMERICA: AI IN BIOTECHNOLOGY MARKET FOR CLINICAL DEVELOPMENT, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 304 LATIN AMERICA: AI IN BIOTECHNOLOGY MARKET FOR MANUFACTURING & SUPPLY CHAIN FUNCTIONS, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 305 LATIN AMERICA: AI IN BIOTECHNOLOGY MARKET FOR LAUNCH & COMMERCIAL FUNCTIONS, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 306 LATIN AMERICA: AI IN BIOTECHNOLOGY MARKET FOR POST-MARKETING SURVEILLANCE & PATIENT SUPPORT FUNCTIONS, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 307 LATIN AMERICA: AI IN BIOTECHNOLOGY MARKET FOR CORPORATE FUNCTIONS, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 308 LATIN AMERICA: AI IN BIOTECHNOLOGY MARKET, BY DEPLOYMENT MODE, 2022–2029 (USD MILLION)
  • TABLE 309 LATIN AMERICA: AI IN BIOTECHNOLOGY MARKET FOR CLOUD-BASED SOLUTIONS, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 310 LATIN AMERICA: AI IN BIOTECHNOLOGY MARKET, BY END USER, 2022–2029 (USD MILLION)
  • TABLE 311 BRAZIL: AI IN BIOTECHNOLOGY MARKET, BY OFFERING, 2022–2029 (USD MILLION)
  • TABLE 312 BRAZIL: AI IN BIOTECHNOLOGY MARKET FOR SERVICES, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 313 BRAZIL: AI IN BIOTECHNOLOGY MARKET, BY FUNCTION, 2022–2029 (USD MILLION)
  • TABLE 314 BRAZIL: AI IN BIOTECHNOLOGY MARKET FOR RESEARCH & DEVELOPMENT FUNCTIONS, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 315 BRAZIL: AI IN BIOTECHNOLOGY MARKET FOR DRUG DISCOVERY, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 316 BRAZIL: AI IN BIOTECHNOLOGY MARKET FOR CLINICAL DEVELOPMENT, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 317 BRAZIL: AI IN BIOTECHNOLOGY MARKET FOR MANUFACTURING & SUPPLY CHAIN FUNCTIONS, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 318 BRAZIL: AI IN BIOTECHNOLOGY MARKET FOR LAUNCH & COMMERCIAL FUNCTIONS, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 319 BRAZIL: AI IN BIOTECHNOLOGY MARKET FOR POST-MARKETING SURVEILLANCE & PATIENT SUPPORT FUNCTIONS, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 320 BRAZIL: AI IN BIOTECHNOLOGY MARKET FOR CORPORATE FUNCTIONS, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 321 BRAZIL: AI IN BIOTECHNOLOGY MARKET, BY DEPLOYMENT MODE, 2022–2029 (USD MILLION)
  • TABLE 322 BRAZIL: AI IN BIOTECHNOLOGY MARKET FOR CLOUD-BASED SOLUTIONS, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 323 BRAZIL: AI IN BIOTECHNOLOGY MARKET, BY END USER, 2022–2029 (USD MILLION)
  • TABLE 324 MEXICO: AI IN BIOTECHNOLOGY MARKET, BY OFFERING, 2022–2029 (USD MILLION)
  • TABLE 325 MEXICO: AI IN BIOTECHNOLOGY MARKET FOR SERVICES, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 326 MEXICO: AI IN BIOTECHNOLOGY MARKET, BY FUNCTION, 2022–2029 (USD MILLION)
  • TABLE 327 MEXICO: AI IN BIOTECHNOLOGY MARKET FOR RESEARCH & DEVELOPMENT FUNCTIONS, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 328 MEXICO: AI IN BIOTECHNOLOGY MARKET FOR DRUG DISCOVERY, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 329 MEXICO: AI IN BIOTECHNOLOGY MARKET FOR CLINICAL DEVELOPMENT, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 330 MEXICO: AI IN BIOTECHNOLOGY MARKET FOR MANUFACTURING & SUPPLY CHAIN FUNCTIONS, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 331 MEXICO: AI IN BIOTECHNOLOGY MARKET FOR LAUNCH & COMMERCIAL FUNCTIONS, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 332 MEXICO: AI IN BIOTECHNOLOGY MARKET FOR POST-MARKETING SURVEILLANCE & PATIENT SUPPORT FUNCTIONS, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 333 MEXICO: AI IN BIOTECHNOLOGY MARKET FOR CORPORATE FUNCTIONS, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 334 MEXICO: AI IN BIOTECHNOLOGY MARKET, BY DEPLOYMENT MODE, 2022–2029 (USD MILLION)
  • TABLE 335 MEXICO: AI IN BIOTECHNOLOGY MARKET FOR CLOUD-BASED SOLUTIONS, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 336 MEXICO: AI IN BIOTECHNOLOGY MARKET, BY END USER, 2022–2029 (USD MILLION)
  • TABLE 337 REST OF LATIN AMERICA: AI IN BIOTECHNOLOGY MARKET, BY OFFERING, 2022–2029 (USD MILLION)
  • TABLE 338 REST OF LATIN AMERICA: AI IN BIOTECHNOLOGY MARKET FOR SERVICES, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 339 REST OF LATIN AMERICA: AI IN BIOTECHNOLOGY MARKET, BY FUNCTION, 2022–2029 (USD MILLION)
  • TABLE 340 REST OF LATIN AMERICA: AI IN BIOTECHNOLOGY MARKET FOR RESEARCH & DEVELOPMENT FUNCTIONS, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 341 REST OF LATIN AMERICA: AI IN BIOTECHNOLOGY MARKET FOR DRUG DISCOVERY, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 342 REST OF LATIN AMERICA: AI IN BIOTECHNOLOGY MARKET FOR CLINICAL DEVELOPMENT, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 343 REST OF LATIN AMERICA: AI IN BIOTECHNOLOGY MARKET FOR MANUFACTURING & SUPPLY CHAIN FUNCTIONS, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 344 REST OF LATIN AMERICA: AI IN BIOTECHNOLOGY MARKET FOR LAUNCH & COMMERCIAL FUNCTIONS, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 345 REST OF LATIN AMERICA: AI IN BIOTECHNOLOGY MARKET FOR POST-MARKETING SURVEILLANCE & PATIENT SUPPORT FUNCTIONS, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 346 REST OF LATIN AMERICA: AI IN BIOTECHNOLOGY MARKET FOR CORPORATE FUNCTIONS, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 347 REST OF LATIN AMERICA: AI IN BIOTECHNOLOGY MARKET, BY DEPLOYMENT MODE, 2022–2029 (USD MILLION)
  • TABLE 348 REST OF LATIN AMERICA: AI IN BIOTECHNOLOGY MARKET FOR CLOUD-BASED SOLUTIONS, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 349 REST OF LATIN AMERICA: AI IN BIOTECHNOLOGY MARKET, BY END USER, 2022–2029 (USD MILLION)
  • TABLE 350 MIDDLE EAST & AFRICA: AI IN BIOTECHNOLOGY MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 351 MIDDLE EAST & AFRICA: AI IN BIOTECHNOLOGY MARKET, BY OFFERING, 2022–2029 (USD MILLION)
  • TABLE 352 MIDDLE EAST & AFRICA: AI IN BIOTECHNOLOGY MARKET FOR SERVICES, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 353 MIDDLE EAST & AFRICA: AI IN BIOTECHNOLOGY MARKET, BY FUNCTION, 2022–2029 (USD MILLION)
  • TABLE 354 MIDDLE EAST & AFRICA: AI IN BIOTECHNOLOGY MARKET FOR RESEARCH & DEVELOPMENT FUNCTIONS, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 355 MIDDLE EAST & AFRICA: AI IN BIOTECHNOLOGY MARKET FOR DRUG DISCOVERY, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 356 MIDDLE EAST & AFRICA: AI IN BIOTECHNOLOGY MARKET FOR CLINICAL DEVELOPMENT, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 357 MIDDLE EAST & AFRICA: AI IN BIOTECHNOLOGY MARKET FOR MANUFACTURING & SUPPLY CHAIN FUNCTIONS, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 358 MIDDLE EAST & AFRICA: AI IN BIOTECHNOLOGY MARKET FOR LAUNCH & COMMERCIAL FUNCTIONS, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 359 MIDDLE EAST & AFRICA: AI IN BIOTECHNOLOGY MARKET FOR POST-MARKETING SURVEILLANCE & PATIENT SUPPORT FUNCTIONS, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 360 MIDDLE EAST & AFRICA: AI IN BIOTECHNOLOGY MARKET FOR CORPORATE FUNCTIONS, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 361 MIDDLE EAST & AFRICA: AI IN BIOTECHNOLOGY MARKET, BY DEPLOYMENT MODE, 2022–2029 (USD MILLION)
  • TABLE 362 MIDDLE EAST & AFRICA: AI IN BIOTECHNOLOGY MARKET FOR CLOUD-BASED SOLUTIONS, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 363 MIDDLE EAST & AFRICA: AI IN BIOTECHNOLOGY MARKET, BY END USER, 2022–2029 (USD MILLION)
  • TABLE 364 GCC COUNTRIES: AI IN BIOTECHNOLOGY MARKET, BY OFFERING, 2022–2029 (USD MILLION)
  • TABLE 365 GCC COUNTRIES: AI IN BIOTECHNOLOGY MARKET FOR SERVICES, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 366 GCC COUNTRIES: AI IN BIOTECHNOLOGY MARKET, BY FUNCTION, 2022–2029 (USD MILLION)
  • TABLE 367 GCC COUNTRIES: AI IN BIOTECHNOLOGY MARKET FOR RESEARCH & DEVELOPMENT FUNCTIONS, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 368 GCC COUNTRIES: AI IN BIOTECHNOLOGY MARKET FOR DRUG DISCOVERY, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 369 GCC COUNTRIES: AI IN BIOTECHNOLOGY MARKET FOR CLINICAL DEVELOPMENT, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 370 GCC COUNTRIES: AI IN BIOTECHNOLOGY MARKET FOR MANUFACTURING & SUPPLY CHAIN FUNCTIONS, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 371 GCC COUNTRIES: AI IN BIOTECHNOLOGY MARKET FOR LAUNCH & COMMERCIAL FUNCTIONS, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 372 GCC COUNTRIES: AI IN BIOTECHNOLOGY MARKET FOR POST-MARKETING SURVEILLANCE & PATIENT SUPPORT FUNCTIONS, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 373 GCC COUNTRIES: AI IN BIOTECHNOLOGY MARKET FOR CORPORATE FUNCTIONS, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 374 GCC COUNTRIES: AI IN BIOTECHNOLOGY MARKET, BY DEPLOYMENT MODE, 2022–2029 (USD MILLION)
  • TABLE 375 GCC COUNTRIES: AI IN BIOTECHNOLOGY MARKET FOR CLOUD-BASED SOLUTIONS, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 376 GCC COUNTRIES: AI IN BIOTECHNOLOGY MARKET, BY END USER, 2022–2029 (USD MILLION)
  • TABLE 377 REST OF MIDDLE EAST & AFRICA: AI IN BIOTECHNOLOGY MARKET, BY OFFERING, 2022–2029 (USD MILLION)
  • TABLE 378 REST OF MIDDLE EAST & AFRICA: AI IN BIOTECHNOLOGY MARKET FOR SERVICES, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 379 REST OF MIDDLE EAST & AFRICA: AI IN BIOTECHNOLOGY MARKET, BY FUNCTION, 2022–2029 (USD MILLION)
  • TABLE 380 REST OF MIDDLE EAST & AFRICA: AI IN BIOTECHNOLOGY MARKET FOR RESEARCH & DEVELOPMENT FUNCTIONS, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 381 REST OF MIDDLE EAST & AFRICA: AI IN BIOTECHNOLOGY MARKET FOR DRUG DISCOVERY, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 382 REST OF MIDDLE EAST & AFRICA: AI IN BIOTECHNOLOGY MARKET FOR CLINICAL DEVELOPMENT, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 383 REST OF MIDDLE EAST & AFRICA: AI IN BIOTECHNOLOGY MARKET FOR MANUFACTURING & SUPPLY CHAIN FUNCTIONS, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 384 REST OF MIDDLE EAST & AFRICA: AI IN BIOTECHNOLOGY MARKET FOR LAUNCH & COMMERCIAL FUNCTIONS, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 385 REST OF MIDDLE EAST & AFRICA: AI IN BIOTECHNOLOGY MARKET FOR POST-MARKETING SURVEILLANCE & PATIENT SUPPORT FUNCTIONS, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 386 REST OF MIDDLE EAST & AFRICA: AI IN BIOTECHNOLOGY MARKET FOR CORPORATE FUNCTIONS, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 387 REST OF MIDDLE EAST & AFRICA: AI IN BIOTECHNOLOGY MARKET, BY DEPLOYMENT MODE, 2022–2029 (USD MILLION)
  • TABLE 388 REST OF MIDDLE EAST & AFRICA: AI IN BIOTECHNOLOGY MARKET FOR CLOUD-BASED SOLUTIONS MODE, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 389 REST OF MIDDLE EAST & AFRICA: AI IN BIOTECHNOLOGY MARKET, BY END USER, 2022–2029 (USD MILLION)
  • TABLE 390 AI IN BIOTECHNOLOGY: DEGREE OF COMPETITION
  • TABLE 391 AI IN BIOTECHNOLOGY MARKET: OFFERING FOOTPRINT
  • TABLE 392 AI IN BIOTECHNOLOGY MARKET: FUNCTION FOOTPRINT
  • TABLE 393 AI IN BIOTECHNOLOGY MARKET: END-USER FOOTPRINT
  • TABLE 394 AI IN BIOTECHNOLOGY: REGION FOOTPRINT
  • TABLE 395 AI IN BIOTECHNOLOGY MARKET: DETAILED LIST OF KEY START-UPS/SMES
  • TABLE 396 AI IN BIOTECHNOLOGY: COMPETITIVE BENCHMARKING OF KEY EMERGING PLAYERS/STARTUPS
  • TABLE 397 AI IN BIOTECHNOLOGY MARKET: PRODUCT LAUNCHES & UPGRADES, JANUARY 2021–AUGUST 2024
  • TABLE 398 AI IN BIOTECHNOLOGY MARKET: DEALS, JANUARY 2021–AUGUST 2024
  • TABLE 399 AI IN BIOTECHNOLOGY MARKET: EXPANSIONS, JANUARY 2021–AUGUST 2024
  • TABLE 400 NVIDIA CORPORATION: COMPANY OVERVIEW
  • TABLE 401 NVIDIA CORPORATION: PRODUCTS OFFERED
  • TABLE 402 NVIDIA CORPORATION: PRODUCT LAUNCHES, JANUARY 2021−AUGUST 2024
  • TABLE 403 NVIDIA CORPORATION: DEALS, JANUARY 2021−AUGUST 2024
  • TABLE 404 ILLUMINA, INC.: COMPANY OVERVIEW
  • TABLE 405 ILLUMINA, INC.: PRODUCTS OFFERED
  • TABLE 406 ILLUMINA, INC.: PRODUCT LAUNCHES, JANUARY 2021−AUGUST 2024
  • TABLE 407 ILLUMINA, INC.: DEALS, JANUARY 2021−AUGUST 2024
  • TABLE 408 EXSCIENTIA: COMPANY OVERVIEW
  • TABLE 409 EXSCIENTIA: PRODUCTS OFFERED
  • TABLE 410 EXSCIENTIA: PRODUCT LAUNCHES, JANUARY 2021−AUGUST 2024
  • TABLE 411 EXSCIENTIA: DEALS, JANUARY 2021−AUGUST 2024
  • TABLE 412 EXSCIENTIA: OTHER DEVELOPMENTS, JANUARY 2021−AUGUST 2024
  • TABLE 413 SCHRÖDINGER, INC.: COMPANY OVERVIEW
  • TABLE 414 SCHRÖDINGER, INC.: PRODUCTS OFFERED
  • TABLE 415 SCHRÖDINGER, INC.: PRODUCT UPGRADES, JANUARY 2021−AUGUST 2024
  • TABLE 416 SCHRÖDINGER, INC.: DEALS, JANUARY 2021−AUGUST 2024
  • TABLE 417 RECURSION PHARMACEUTICALS, INC.: COMPANY OVERVIEW
  • TABLE 418 RECURSION PHARMACEUTICALS, INC.: PRODUCTS OFFERED
  • TABLE 419 RECURSION PHARMACEUTICALS, INC.: DEALS, JANUARY 2021−AUGUST 2024
  • TABLE 420 RECURSION PHARMACEUTICALS, INC.: EXPANSIONS, JANUARY 2021−AUGUST 2024
  • TABLE 421 SOPHIA GENETICS: COMPANY OVERVIEW
  • TABLE 422 SOPHIA GENETICS: PRODUCTS OFFERED
  • TABLE 423 SOPHIA GENETICS: PRODUCT LAUNCHES, JANUARY 2021−AUGUST 2024
  • TABLE 424 SOPHIA GENETICS: DEALS, JANUARY 2021−AUGUST 2024
  • TABLE 425 PREDICTIVE ONCOLOGY: COMPANY OVERVIEW
  • TABLE 426 PREDICTIVE ONCOLOGY: PRODUCTS OFFERED
  • TABLE 427 PREDICTIVE ONCOLOGY: PRODUCT LAUNCHES, JANUARY 2021−AUGUST 2024
  • TABLE 428 PREDICTIVE ONCOLOGY: DEALS, JANUARY 2021−AUGUST 2024
  • TABLE 429 BENEVOLENTAI: COMPANY OVERVIEW
  • TABLE 430 BENEVOLENTAI: PRODUCTS OFFERED
  • TABLE 431 BENEVOLENTAI: DEALS, JANUARY 2021−AUGUST 2024
  • TABLE 432 EUROFINS DISCOVERY: COMPANY OVERVIEW
  • TABLE 433 EUROFINS DISCOVERY: PRODUCTS OFFERED
  • TABLE 434 EUROFINS DISCOVERY: PRODUCT LAUNCHES, JANUARY 2021−AUGUST 2024
  • TABLE 435 EUROFINS DISCOVERY: DEALS, JANUARY 2021−AUGUST 2024
  • TABLE 436 EUROFINS DISCOVERY: EXPANSIONS, JANUARY 2021−AUGUST 2024
  • TABLE 437 XTALPI INC.: COMPANY OVERVIEW
  • TABLE 438 XTALPI INC.: PRODUCTS OFFERED
  • TABLE 439 XTALPI INC.: DEALS, JANUARY 2021−AUGUST 2024
  • TABLE 440 DNANEXUS, INC.: COMPANY OVERVIEW
  • TABLE 441 DNANEXUS, INC.: PRODUCTS OFFERED
  • TABLE 442 DNANEXUS, INC.: DEALS, JANUARY 2021−AUGUST 2024
  • TABLE 443 DNANEXUS, INC: OTHER DEVELOPMENTS, JANUARY 2021–AUGUST 2024
  • TABLE 444 NUMEDII, INC.: COMPANY OVERVIEW
  • TABLE 445 NUMEDII, INC.: PRODUCTS OFFERED
  • TABLE 446 BPGBIO, INC.: COMPANY OVERVIEW
  • TABLE 447 BPGBIO, INC.: PRODUCTS OFFERED
  • TABLE 448 BPGBIO, INC.: DEALS, JANUARY 2021−AUGUST 2024
  • TABLE 449 IKTOS: COMPANY OVERVIEW
  • TABLE 450 IKTOS: PRODUCTS OFFERED
  • TABLE 451 IKTOS: DEALS, JANUARY 2021−AUGUST 2024
  • TABLE 452 INSILICO MEDICINE: COMPANY OVERVIEW
  • TABLE 453 INSILICO MEDICINE: PRODUCTS OFFERED
  • TABLE 454 LOGICA: COMPANY OVERVIEW
  • TABLE 455 LOGICA: PRODUCTS OFFERED
  • TABLE 456 AMERICAN CHEMICAL SOCIETY: COMPANY OVERVIEW
  • TABLE 457 AMERICAN CHEMICAL SOCIETY: PRODUCTS OFFERED
  • TABLE 458 AGANITHA AI INC.: COMPANY OVERVIEW
  • TABLE 459 AGANITHA AI INC.: PRODUCTS OFFERED
  • TABLE 460 AGANITHA AI INC.: DEALS, JANUARY 2021−AUGUST 2024
LIST OF FIGURES
 
  • FIGURE 1 AI IN BIOTECHNOLOGY MARKET SEGMENTATION & REGIONAL SCOPE
  • FIGURE 2 RESEARCH DESIGN
  • FIGURE 3 PRIMARY SOURCES
  • FIGURE 4 BREAKDOWN OF PRIMARY INTERVIEWS (DEMAND SIDE): BY COMPANY TYPE, DESIGNATION, AND REGION
  • FIGURE 5 MARKET SIZE ESTIMATION: REVENUE SHARE ANALYSIS
  • FIGURE 6 TOP-DOWN APPROACH
  • FIGURE 7 AI IN BIOTECHNOLOGY MARKET: CAGR PROJECTIONS
  • FIGURE 8 CAGR PROJECTIONS: SUPPLY-SIDE ANALYSIS
  • FIGURE 9 DATA TRIANGULATION
  • FIGURE 10 AI IN BIOTECHNOLOGY MARKET, BY OFFERING, 2024 VS. 2029 (USD MILLION)
  • FIGURE 11 AI IN BIOTECHNOLOGY MARKET, BY FUNCTION, 2024 VS. 2029 (USD MILLION)
  • FIGURE 12 AI IN BIOTECHNOLOGY MARKET, BY DEPLOYMENT MODE, 2024 VS. 2029 (USD MILLION)
  • FIGURE 13 AI IN BIOTECHNOLOGY MARKET, BY END USER, 2024 VS. 2029 (USD MILLION)
  • FIGURE 14 AI IN BIOTECHNOLOGY MARKET: GEOGRAPHICAL SNAPSHOT
  • FIGURE 15 GROWING FOCUS ON COST-EFFECTIVE PROCESSES AND FAVORABLE GOVERNMENT SUPPORT AND FUNDING TO DRIVE MARKET
  • FIGURE 16 NORTH AMERICA TO DOMINATE AI IN BIOTECHNOLOGY MARKET DURING FORECAST PERIOD
  • FIGURE 17 PHARMACEUTICAL COMPANIES IN NORTH AMERICA ACCOUNTED FOR LARGEST MARKET SHARE IN 2023
  • FIGURE 18 INDIA TO REGISTER HIGHEST GROWTH RATE DURING FORECAST PERIOD
  • FIGURE 19 EMERGING ECONOMIES TO REGISTER HIGHER GROWTH RATES DURING FORECAST PERIOD
  • FIGURE 20 AI IN BIOTECHNOLOGY MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES
  • FIGURE 21 AI IN BIOTECHNOLOGY MARKET: ECOSYSTEM ANALYSIS
  • FIGURE 22 AI IN BIOTECHNOLOGY MARKET: VALUE CHAIN ANALYSIS
  • FIGURE 23 AI IN BIOTECHNOLOGY MARKET: PORTER’S FIVE FORCES ANALYSIS
  • FIGURE 24 PATENT PUBLICATION TRENDS IN AI IN BIOTECHNOLOGY MARKET, 2015–2024
  • FIGURE 25 PATENT ANALYSIS OF AI IN BIOTECHNOLOGY MARKET, JANUARY 2015–AUGUST 2024
  • FIGURE 26 EVOLUTION OF AI IN BIOTECHNOLOGY MARKET
  • FIGURE 27 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS OF TOP 3 END USERS
  • FIGURE 28 KEY BUYING CRITERIA FOR TOP 3 END USERS
  • FIGURE 29 TRENDS & DISRUPTIONS IMPACTING CUSTOMERS’ BUSINESSES
  • FIGURE 30 AI IN BIOTECHNOLOGY MARKET: INVESTMENT & FUNDING SCENARIO
  • FIGURE 31 MARKET POTENTIAL OF AI/GENERATIVE AI ON AI IN BIOTECHNOLOGY SOLUTIONS
  • FIGURE 32 NUMBER OF AI-DISCOVERED MOLECULES IN CLINICAL TRIALS
  • FIGURE 33 NORTH AMERICA: AI IN BIOTECHNOLOGY MARKET SNAPSHOT
  • FIGURE 34 ASIA PACIFIC: AI IN BIOTECHNOLOGY MARKET SNAPSHOT
  • FIGURE 35 KEY DEVELOPMENTS OF MAJOR PLAYERS BETWEEN JANUARY 2021 AND JUNE 2024
  • FIGURE 36 REVENUE ANALYSIS OF KEY PLAYERS IN AI IN BIOTECHNOLOGY MARKET, 2019–2023 (USD BILLION)
  • FIGURE 37 MARKET SHARE ANALYSIS OF KEY PLAYERS IN AI IN BIOTECHNOLOGY MARKET (2023)
  • FIGURE 38 RANKING OF KEY PLAYERS IN AI IN BIOTECHNOLOGY MARKET, 2023
  • FIGURE 39 AI IN BIOTECHNOLOGY MARKET: COMPANY EVALUATION MATRIX (KEY PLAYERS), 2023
  • FIGURE 40 AI IN BIOTECHNOLOGY MARKET: COMPANY FOOTPRINT
  • FIGURE 41 AI IN BIOTECHNOLOGY MARKET: COMPANY EVALUATION MATRIX (START-UPS/SMES), 2023
  • FIGURE 42 EV/EBITDA OF KEY VENDORS
  • FIGURE 43 YEAR-TO-DATE (YTD) PRICE TOTAL RETURN AND 5-YEAR STOCK BETA OF AI IN BIOTEHNOLOGY SOLUTION VENDORS
  • FIGURE 44 AI IN BIOTECHNOLOGY MARKET: BRAND/PRODUCT COMPARATIVE ANALYSIS
  • FIGURE 45 NVIDIA CORPORATION: COMPANY SNAPSHOT (2024)
  • FIGURE 46 ILLUMINA, INC.: COMPANY SNAPSHOT (2023)
  • FIGURE 47 EXSCIENTIA: COMPANY SNAPSHOT (2023)
  • FIGURE 48 SCHRÖDINGER, INC.: COMPANY SNAPSHOT (2023)
  • FIGURE 49 RECURSION PHARMACEUTICALS, INC.: COMPANY SNAPSHOT (2023)
  • FIGURE 50 SOPHIA GENETICS: COMPANY SNAPSHOT (2022)
  • FIGURE 51 PREDICTIVE ONCOLOGY: COMPANY SNAPSHOT (2023)
  • FIGURE 52 BENEVOLENTAI: COMPANY SNAPSHOT (2023)
  • FIGURE 53 EUROFINS DISCOVERY: COMPANY SNAPSHOT (2023)
  • FIGURE 54 XTALPI INC.: COMPANY SNAPSHOT (2023)

 

This research study involved the extensive use of both primary and secondary sources. It involved the analysis of various factors affecting the industry to identify the segmentation types, industry trends, key players, the competitive landscape of market players, and key market dynamics such as drivers, opportunities, challenges, restraints, and key player strategies.

Secondary Research

This research study extensively utilized secondary sources, including directories, databases such as Dun & Bradstreet, Bloomberg Businessweek, and Factiva, as well as white papers, annual reports, and companies' house documents. The aim of the secondary research was to gather and analyze information for a comprehensive and commercially focused study of the AI in biotechnology market, encompassing technical aspects and market dynamics. It also facilitated the identification of key players, market classification, industry trends, geographical markets, and significant market-related developments. Additionally, a database of prominent industry leaders was compiled through secondary research.

Primary Research

In the primary research process, various supply-side and demand-side sources were interviewed to obtain qualitative and quantitative information for this report. Primary sources from the supply side included industry experts such as CEOs, vice presidents, marketing and sales directors, technology & innovation directors, engineers, and related key executives from various companies and organizations operating in the AI in biotechnology market. Primary sources from the demand side included personnel from pharmaceutical & biotechnology companies, government organizations, research institutes and hospitals (small, medium-sized, and large hospitals).

A breakdown of the primary respondents is provided below

*Others include sales managers, marketing managers, and product managers.

Note: Tiers are defined based on a company’s total revenue, as of 2022: Tier 1 = >USD 1 billion, Tier 2 = USD 500 million to USD 1 billion, and Tier 3 = < USD 500 million.

To know about the assumptions considered for the study, download the pdf brochure

Market Size Estimation

The total size of the AI in biotechnology market was determined after data triangulation through the two approaches mentioned below. After the completion of each approach, the weighted average of these approaches was taken based on the level of assumptions used in each approach.

Data Triangulation

The size of the AI in biotechnology market was estimated through segmental extrapolation using the bottom-up approach. The methodology used is as given below:-

  • Revenues for individual companies were gathered from public sources and databases.
  • Shares of leading players in the AI in biotechnology market were gathered from secondary sources to the extent available. In certain cases, shares of AI in biotechnology businesses have been ascertained after a detailed analysis of various parameters including product portfolios, market positioning, selling price, and geographic reach & strength.
  • Individual shares or revenue estimates were validated through interviews with experts.
  • The total revenue in the AI in biotechnology market was determined by extrapolating the market share data of major companies.

Market Definition

The AI in biotechnology market refers to the use of artificial intelligence technologies to streamline and enhance various processes within biotechnology, particularly in drug discovery, research and development (R&D), clinical trials, supply chain management, and manufacturing. AI technologies like machine learning, deep learning, and predictive analytics enable more efficient molecular design, biomarker discovery, clinical trial optimization, and patient monitoring. AI technologies and their ability to reduce drug discovery timelines, improve clinical trial efficiency, and optimize biotech manufacturing processes

Stakeholders

  • Healthcare IT Service Providers
  • Pharmaceutical/Biopharmaceutical Companies
  • Biotechnology Firms
  • AI Technology Providers
  • Academic & Research Institutions
  • Academic Medical Centres/Universities/Hospitals
  • Regulatory Agencies
  • Clinical Research Organizations (CROs)
  • Genomic Testing Labs
  • Government Agencies
  • Startups in AI and Biotech
  • Pharmaceutical Supply Chain Partners
  • Consulting Firms
  • Clinical Trial Management Systems Providers
  • Bioinformatics Companies

Report Objectives

  • To define, describe, and forecast the AI in biotechnology market based on offering, function, deployment mode, end user, and region
  • To provide detailed information regarding the major factors influencing the market growth (such as drivers, restraints, opportunities, and challenges)
  • To analyze the micro markets with respect to individual growth trends, prospects, and contributions to the overall AI in biotechnology market
  • To analyze the opportunities for stakeholders and provide details of the competitive landscape for market leaders
  • To forecast the size of the market segments with respect to five main regions, namely, North America, Europe, the Asia Pacific, Latin America, the Middle East & Africa.
  • To profile the key players and analyze their market shares and core competencies.
  • To track and analyze competitive developments such as partnerships, collaborations, acquisitions, expansion, agreements, investment, and product launches  in the overall AI in biotechnology market
  • To benchmark players within the market using the proprietary "Competitive Leadership Mapping" framework, which analyzes market players on various parameters within the broad categories of business and product strategy.

Previous Versions of this Report

"Our USP is "providing game-changing business opportunities reports with free customization" - so please feel free to provide us with your specific areas of interest / business challenges in much greater detail !!"

We appreciate your interest in this report. Once you fill out the form, you'll be immediately directed to an exclusive solution tailored to your needs. This high-value offering can help boost your revenue by 30% - a must-see opportunity for anyone looking to maximize growth.


By clicking the "Submit" button, you are agreeing to the Terms of Use and Privacy Policy.

Custom Market Research Services

We Will Customise The Research For You, In Case The Report Listed Above Does Not Meet With Your Requirements

Get 10% Free Customisation

Growth opportunities and latent adjacency in AI in Biotechnology Market

DMCA.com Protection Status